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Summary
Background Although several large-scale randomised controlled trials have shown the efficacy of digital cognitive 
behavioural therapy for insomnia (dCBT-I), there is a need to validate widespread dissemination of dCBT-I using 
recommended key outcomes for insomnia. We investigated the effect of a fully automated dCBT-I programme on 
insomnia severity, sleep–wake patterns, sleep medication use, and daytime impairment.
Methods We did a parallel-group superiority randomised controlled trial comparing dCBT-I with online patient 
education about sleep. The interventions were available through a free-to-access website, publicised throughout 
Norway, which incorporated automated screening, informed consent, and randomisation procedures, as well 
as outcome assessments. Adults (age ≥18 years) who had regular internet access and scored 12 or higher on the 
Insomnia Severity Index (ISI) were eligible for inclusion, and were allocated (1:1) to receive dCBT-I (consisting 
of six core interactive sessions to be completed over 9 weeks) or patient education (control group). Participants were 
masked to group assignment and had no contact with researchers during the intervention period. The primary 
outcome was the change in ISI score from baseline to 9-week follow-up, assessed in the intention-to-treat population. 
This trial is registered with ClinicalTrials.gov (NCT02558647) and is ongoing, with 2-year follow-up assessments 
planned.
Findings Between Feb 26, 2016, and July 1, 2018, 5349 individuals commenced the online screening process, of which 
1497 were ineligible or declined to participate, 2131 discontinued the screening process, and 1721 were randomly allocated 
(868 to receive dCBT-I and 853 to receive patient education). At 9-week follow-up, 584 (67%) participants in the dCBT-I 
group and 534 (63%) in the patient education group completed the ISI assessment. The latent growth model showed that 
participants in the dCBT-I group had a significantly greater reduction in ISI scores from baseline (mean score 19·2 
[SD 3·9]) to 9-week follow-up (10·4 [6·2]) than those in the patient education group (from 19·6 [4·0] to 15·2 [5·3]; 
estimated mean difference –4·7 (95% CI –5·4 to –4·1; Cohen’s d –1·21; p<0·001). Compared with patient education, the 
number needed to treat with dCBT-I was 2·7 (95% CI 2·4 to 3·2) for treatment response (ISI score reduction ≥8) and 
3·2 (2·8 to 3·8) for insomnia remission (ISI score <8). No adverse events were reported to the trial team.
Interpretation dCBT-I is effective in reducing the severity of symptoms associated with the insomnia disorder. These 
findings support the widespread dissemination of dCBT-I. Future research is needed to identify the moderators 
of response and to improve targeting.
Funding Norwegian Research Council; Liaison Committee for Education, Research and Innovation in Central Norway.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Insomnia has an estimated prevalence of around 10–15% 
in adults.1,2 Internationally, most treatment guidelines 
advocate the use of psychological inter ventions such as 
cognitive behavioural therapy for insomnia (CBT-I), 
either as a primary intervention or as an adjunct to short-
term courses of medications.3,4 In reality, demand for 
face-to-face CBT-I exceeds supply. Many general prac-
titioners are unable to prescribe this option, or there is a 
long waiting time until a trained therapist is available. 
Difficulties in access to guideline-recommended therapy 
have encouraged the develop ment of online interventions, 
and a number of automated and therapist-guided 
versions of digital CBT-I (dCBT-I) are now available.
Randomised controlled trials (RCTs) of various versions 
of dCBT-I have shown reductions in the symptoms of 
insomnia and improvements in sleep–wake patterns, 
both in the short term and at 1-year follow-up 
(n>300 adults);5 reductions in depressive symptoms 
(n>1000 adults with insomnia and symptoms of dep-
ression);6 and improved functional health, psychological 
wellbeing, and sleep-related quality of life (n>1700 adults).7 
Additionally, in a sample of more than 3000 students, 
Freeman and col leagues8 found that dCBT-I was 
associated with signifi cantly greater reductions in 
insomnia severity, paranoia, and hallu cinations when 
compared with treatment as usual. Of the three large 
(n>1000) RCTs, only the trial by Freeman and colleagues8 
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included the Insomnia Severity Index (ISI) in the 
assessments, and none included sleep diaries. The ISI 
and sleep diaries are recommended key outcome mea-
sures for studies and clinical trials of insomnia,9 and 
omitting these measures limits the com parability of the 
magnitude of benefits among different dCBT-I models, 
or comparisons with other insomnia interventions such 
as face-to-face interventions. Furthermore, Freeman and 
colleagues’ study8 was done on a student sample (mean 
age 25 years), which also limits generalisability, and 
attrition in that study was high, with only 18% of 
participants completing the dCBT-I intervention. In 
addition, the use of a treatment-as-usual control group 
(as in Freeman and colleagues’ trial) reduces com para-
bility across trials and can lead to inflated effect estimates. 
Thus, there is a need to investigate the effect of dCBT-I in 
comparison with a more robust and controlled condition. 
To our knowledge, no previous large-scale trial has inves-
tigated how automated dCBT-I programmes affect 
participants’ use of sleep medication. This factor is imp-
ortant because sleep medication is recommended as a 
short-term solution only, but often becomes a long-term 
treatment by default.
To date, most RCTs of dCBT-I have been done on 
subpopulations in English-speaking countries, such as 
the USA, the UK, or Australia. To validate broad diss emin-
ation of dCBT-I, investigation of the effect of the inter-
vention in non-English speaking countries, as well as in 
the general adult population, and with use of a pragmatic 
approach with minimal exclusion criteria, is necessary.
To address crucial knowledge gaps regarding dCBT-I, 
we did an RCT using a fully automated screening and 
intervention programme among adults recruited from 
the general population in Norway. We examined the 
effects of dCBT-I compared with an online patient sleep 
education programme on self-reported insomnia symp-
toms, sleep–wake patterns, use of sleep medication, and 
other key markers of health and wellbeing, such as 
daytime fatigue, psychological distress, and perceived 
physical and mental health.
Methods
Study design and participants
We followed the CONSORT guidelines for a parallel-
group, superiority RCT, comparing fully automated 
dCBT-I (a Norwegian-language version of Sleep Healthy 
Using the Internet [SHUTi]) with online patient edu-
cation about sleep.
For the purpose of recruitment, the RCT was 
publicised in several ways. Information about the trial 
and about its website was made available in waiting 
rooms at general practitioner or family doctor surgeries 
and at primary care and municipal health-care facilities 
throughout Norway (eg, prompt mental health-care 
clinics, which are similar to Improving Access to 
Psychological Therapies clinics in England, and Healthy 
Life Centres in Norway [Frisklivssentraler]). A link to 
the trial website was made available through the 
websites of other relevant institutions (eg, Healthy Life 
Centre websites and the website of the Norwegian 
Competence Centre for Sleep Disorders). During the 
recruitment period, the Norwegian University of 
Science and Technology, the Norwegian Institute of 
Public Health, and the Central Norway Regional Health 
Authority pub licised the RCT (eg, through news about 
the trial on their websites and Facebook), and interviews 
with members of the research team were published in 
local and national newspapers.
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Research in context
Evidence before this study
Treatment guidelines for chronic insomnia advocate the use 
of cognitive behavioural therapy for insomnia (CBT-I), yet the use 
of CBT-I has been limited by the availability of therapists. Self-
guided and fully automated digital versions of CBT-I (dCBT-I) 
have been created, in part, to address this limitation, and 
numerous systematic reviews and meta-analyses have 
highlighted their efficacy. Three previous randomised controlled 
trials have evaluated the effects of dCBT-I in more than 
1000 participants, and have shown significant reductions in the 
severity and symptoms of insomnia, as well as in associated 
aspects of health and wellbeing, including depressive symptoms, 
functional health, psychological wellbeing, and sleep-related 
quality of life.
Added value of this study
This study is one of the largest randomised controlled trials 
to examine the efficacy of a fully automated version of dCBT-I 
in a community-based sample of adults with significant levels 
of insomnia. We included outcomes based on the 
recommended standard measures of insomnia for adults, 
namely changes in Insomnia Severity Index score and 
sleep–wake patterns prospectively assessed with use of sleep 
diaries, as well as assessing use of sleep medication. The 
findings indicate that dCBT-I is effective in reducing both 
night-time and daytime impairment associated with insomnia 
disorder, while being associated with reduced use of sleep 
medication.
Implications of all the available evidence
Evidence supports the broad dissemination of dCBT-I in the 
general adult population, although it remains unclear how to 
optimally disseminate and target such interventions. Although 
a rapid implementation of new evidence-based innovations is 
important, it is also important to monitor the degree to which 
the efficacy shown in trials translates into clinical effectiveness, 
and to identify the optimal balance between therapist-delivered 
and self-guided interventions.
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A website was made publicly available during the 
recruitment period, and potential participants could 
register and complete an online screening test to assess 
their eligibility for inclusion. Individuals with regular 
internet access were eligible to participate if they were aged 
18 years or older, and scored 12 or higher on the ISI10 (a 
score considered to have a high accuracy for diagnosing 
insomnia disorder [unpublished data]). Individuals were 
excluded if they met one or more of the following criteria: 
scored more than 10 on the Epworth Sleepiness Scale11 
(sug gestive of sleep apnoea and hypersomnia); were at risk 
of sleep apnoea, based on pre-selected screening questions 
(self-reported regular snoring and breathing problems 
with difficulties staying awake during the day); had a self-
reported medical condition for which an automated 
dCBT-I pro gramme might be contraindicated (ie, epilepsy, 
bipolar disorder, schizophrenia or psychotic disorders, or 
recent cardiac surgery); or were currently engaged in 
night-time shift work.
Eligible individuals were subsequently shown two on-
screen notifications. The first stated that the online 
intervention included some text-heavy elements, and 
that if they had reading difficulties or a reading disability 
(eg, dyslexia), they might find sections of the programme 
difficult to follow (individuals were offered an option to 
opt-out at this point). The second notification high-
lighted that the intervention required many individuals 
to actively change their patterns of behaviour, and again 
offered an opt-out or an option to delay entry to the trial 
if the individual was unsure about whether they could 
set aside sufficient time to participate in the full course 
of therapy (six sessions over 6–9 weeks). Following 
these notifications, potential partici pants were asked to 
indicate whether they wished to continue and be incl-
uded in the randomisation process. A positive answer 
resulted in the individual being directed to the online 
consent form, which had to be signed electronically. 
After completion of the consent procedure, individuals 
were assigned per sonal login details to access the base-
line assessment. All participants gave written informed 
consent. The trial protocol was prospectively approved 
by the Regional Committees for Medical and Health 
Research Ethics in South East Norway (2015/134). All 
personal data collected in this trial were anonymised. 
The trial protocol has been published elsewhere.12 The 
patient user group for the Central Norway Health Trust 
(Regionalt brukerutvalg, Helse Midt-Norge) was 
consulted about the trial design and the original protocol 
(as submitted for funding), and their feedback informed 
the aims of the trial and the study design (eg, the 
assessments included and online screening procedure). 
The group also endorsed and supported the final 
research protocol as submitted for ethical approval.12
Randomisation and masking
Individuals who met all eligibility criteria and provided 
online written informed consent were randomly allocated 
(1:1) to receive either dCBT-I or patient sleep education, 
with no stratification. The randomisation procedure was 
integrated into the study platform and fully automated; 
the research team did not have access to the computerised 
process and could not influence randomisation in any 
way. All statistical analyses were done by a researcher 
(ORFS) who was masked to group allocation.
Participants were masked to their group assignment, 
although it is possible that many were able to deduce the 
condition to which they were allocated on the basis of 
programme content. As the interventions were fully auto-
mated and delivered online, there was no contact between 
researchers and participants during the inter vention 
period. If technical problems arose with delivery of the 
online programme or completion of assessments (eg, for-
getting the username or password), a technician could 
assist the participant via email or telephone.
Procedures
The content of the dCBT-I and patient education 
interventions were translated into Norwegian language 
by clinical sleep specialists in Norway and have been 
tested in a smaller-scale study by the investigators.13
The dCBT-I programme (SHUTi)14 consists of six fully 
automated and interactive online sessions designed to be 
completed within a 9-week intervention period (table 1). 
The sessions cover the primary topics addressed in face-to-
face CBT-I,15 including sleep restriction, stimulus control, 
cognitive restructuring, sleep hygiene, and re lapse preven-
tion. By using information and feedback from the indivi-
dual, elements of the SHUTi programme are tailored to 
the user (as described by Thorndike and colleagues).16
The patient education programme is similar to the 
control interventions used in other RCTs of dCBT-I, 
For the study website see 
https://sovnmestring.no
Description of session Participants in dCBT-I 
group who completed 
session (n=868)
Core 1: overview Reviews the nature of insomnia and how the programme 
works; the participants identify their sleep problems and 
set up personal treatment goals
748 (86%)
Core 2: behaviour 
and sleep 1
Focuses on how behavioural changes can improve sleep, 
with a special emphasis on sleep restriction
641 (74%)
Core 3: behaviour 
and sleep 2
Focuses on how behavioural changes can improve sleep, 
with a special emphasis on stimulus control
563 (65%)
Core 4: sleep 
and thoughts
Focuses on addressing and changing beliefs and thoughts 
that might impair sleep (eg, excessive worrying about the 
possible consequences of insomnia)
503 (58%)
Core 5: sleep 
hygiene
Teaches about lifestyle and environmental factors that 
might interfere with sleep (eg, caffeine and nicotine intake, 
and electronic media use in bed)
448 (52%)
Core 6: relapse 
prevention
Focuses on integrating the behavioural, educational, and 
cognitive components from the former cores to develop 
strategies to avoid future episodes of poor sleep from 
developing into full-blown chronic insomnia
402 (46%)
No data were available on the number of participants in the patient education control group who read the content in 
its entirety. dCBT-I=digital cognitive behavioural therapy for insomnia.
Table 1: Description and completion rates of dCBT-I sessions during the intervention period
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including previous trials of SHUTi.5,13 The patient edu-
cation website provides fixed information about the 
prevalence, causes, and consequences of insomnia, the 
symptoms of insomnia, when to seek input from a health 
professional, as well as basic lifestyle, environmental, 
and behavioural recommendations that might help to 
improve sleep (ie, sleep hygiene education). The content 
included in the patient education programme was based 
on a review of established insomnia education websites.5 
There are both similarities and important differences 
between the patient education programme and the 
SHUTi programme. Both provide the user with cognitive 
behavioural therapy principles and offer a method to 
keep ongoing sleep diaries, but the SHUTi programme 
does so through online tools and weekly interactive 
sessions, whereas the patient education pro gramme does 
so through provision of printable documents.
At baseline and 9-week follow-up, all participants 
were asked to complete 10 days of sleep diaries within a 
14-day period (including daily self-rating of sleep–wake 
patterns).17 From the sleep diary, we extracted infor-
mation on sleep onset latency (min), wake time after 
sleep onset (min), early morning awakening (min; 
defined as the time between final awakening and 
getting out of bed), total sleep time (h), time in bed (h), 
and sleep efficiency (total sleep time as a percentage of 
time in bed). Participants also completed the ISI, a 
seven-item self-report instrument with good psycho-
metric properties, which assesses core symptoms of 
insomnia (with a higher score indicative of greater 
severity) and is validated for online use. The ISI can 
continuously measure insomnia severity, and can also 
be used to assess remission (score <8) and response to 
inter ventions (reduction of ≥8 points from baseline).15
Because the ISI was used to assess eligibility for 
partici pation, we supplemented this insomnia measure 
with the Bergen Insomnia Scale (BIS),18 a six-item rating 
scale (with higher scores representing greater symptoma-
tology) that assesses the severity of symptoms of 
insomnia that are listed in the diagnostic criteria of the 
Diagnostic and Statistical Manual of Mental Disorders 
(4th edition).19
Use of sleep medication was assessed at baseline and at 
9-week follow-up by the sleep diary item “did you take any 
over-the-counter or prescription medi cation(s) to help you 
sleep?” (answered ”yes” or “no”). Patients were coded as 
using sleep medication at either timepoint if they reported 
using sleeping medication for one or more days.
At baseline, participants self-reported demographic 
information and any ongoing medical or mental health 
condition (selecting items from a pre-specified list 
which included cardiac, endocrine, renal, respiratory, 
skin, joint, and other problems). The mental health 
conditions listed included anxiety, depression, post-
traumatic stress disorder, alcohol or substance use dis-
orders, eating disorder, attention-deficit hyperactivity 
disorder, psychosis, and personality disorders.
Participants were also asked to complete several other 
questionnaires at baseline at a 9-week follow-up: the 
14-item Hospital Anxiety and Depression Scale (HADS), 
as a measure of general psychological distress (with 
higher scores indicative of greater psychological distress);20 
the 11-item Chalder Fatigue Questionnaire (CFQ),21 which 
measures physical and psychological fatigue (with higher 
scores indicating greater daytime functional impairment 
[ie, more fatigue]), with two additional items that address 
the duration and intensity of any complaints; and the 
12-Item Short-Form Health Survey (SF-12),22 which ass-
esses an individual’s perceived physical and mental health 
status, as a general measure of health-related qua lity of 
life (with lower scores indicative of worse physical or 
mental health).
From week 9 after randomisation, all participants 
received daily email reminders to complete the online 
follow-up questionnaire, including the ISI, BIS, HADS, 
CFQ, and SF-12, as well as 10 days of sleep diaries.
Adverse events were not assessed at week 9 post-
randomisation. However, participants were generally enc-
ouraged to contact the trial team if they had questions or 
experienced any problems (related to their health or 
technical issues). CBT-I is generally regarded as an inter-
vention with minimal adverse effects, and previous large-
scale dCBT-I trials have reported no adverse events.7,8
Outcomes
The primary outcome was change in ISI score from baseline 
to week 9 in the intention-to-treat population. The secondary 
outcome measures reported in this Article consisted of daily 
self-rating of sleep–wake patterns (reported using the 
consensus sleep diary), use of sleep medications, BIS score, 
HADS score, CFQ score, and SF-12 score. For all outcome 
variables, the observed scores at baseline and 9-week 
follow-up were modelled by a random intercept and a fixed 
slope, and the effect of the intervention was estimated by 
using the group variable (dCBT-I vs patient education) as a 
predictor of the slope. For CFQ, mean values were used, 
whereas for ISI, BIS, and HADS, a total score was 
calculated. For SF-12, we used the scoring procedure 
described by Ware and colleagues.22
Future analyses, including of sick leave and health 
resource use, are also planned and will require 2-year 
post-randomisation follow-up, as described in the pro-
tocol.12 These data will be available from the Norwegian 
national registers in the next few years.
Statistical analysis
Based on previously published RCTs of dCBT-I com-
pared with patient education,5,6 a large effect size 
(Cohen’s d>|0·8|) was expected for the difference in the 
primary outcome measure (change in ISI score). With 
an antici pated attrition rate of 50% of the recruited 
sample,6 486 participants (243 per group) would suffice 
to detect a moderate-to-large effect size at p<0·05 and 
with 80% statistical power. However, to account for the 
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2-year follow-up analysis, we decided a priori to recruit 
a minimum sample size of 1500 to provide sufficient 
statistical power (80%) to detect significant differences 
(p<0·05) in sick leave and health care use. As the 
recruitment process was automated and could not be 
viewed by investigators in real time (because of masking 
procedures), the researchers received updates on the 
recruited sample size every 2 months. Therefore, the 
final sample size exceeded the planned sample size.
All reported analyses were done on the intention-to-treat 
population, unless otherwise stated. Mplus version 8.2 was 
used to analyse the effect of the intervention, and SPSS 
version 25 for additional analyses (eg, analyses of baseline 
characteristics).
To examine the effects of dCBT-I on the primary and 
secondary outcomes, the observed scores were analysed 
by means of latent growth models in Mplus. The observed 
scores before and after the intervention were modelled by 
a random intercept and a fixed slope. The effect of the 
intervention was estimated by using the group variable 
(dCBT-I vs patient education) as a pre dictor of the slope. 
This procedure yields identical estimates for the inter-
vention effect as a linear mixed model with random 
intercept. Between-group effect sizes (Cohen’s d) were 
calcu lated by dividing the mean difference in estimated 
change in scores from baseline to 9-week follow-up 
assess ment by the pooled SD at baseline. Robust 
maximum likelihood was used as the estimator, providing 
unbiased estimates under the assumption of data being 
missing at random,23 which might be partly met through 
the inclusion of baseline scores to the model.
As some data for week 9 outcome ratings could have 
been missing not at random, the robustness of the results 
under the missing-at-random assumption were tested by 
sensitivity analyses in which the missing scores at follow-
up were replaced by baseline values for that individual. We 
also conducted two additional, more rig orous, sensitivity 
analyses: one in which missing post-intervention scores 
were replaced by pre-intervention scores multiplied by 
1·25 in the dCBT-I group and by 1·00 in the control group; 
and another in which missing post-intervention scores 
were replaced by pre-intervention scores multiplied by 
1·25 in the dCBT-I group and by 0·75 in the control group. 
More extreme scenarios were considered to be very 
unrealistic.
The proportions of participants per group who met the 
ISI criteria for response and remission were compared 
using Pearson’s χ² test and the Newcombe hybrid score CI.
Number-needed-to-treat (NNT) analyses (with 95% CIs) 
for dCBT-I compared with patient education were done 
for categorical outcomes (ie, the proportion of individuals 
per group who met ISI criteria for response and remission 
at follow-up.24
When examining compliance, we did a complier-average 
causal effect (CACE) analysis, which is considered to be 
more rigorous than a per-protocol analysis. A mixture 
model was used in which the intervention effect was 
allowed to vary across a non-complier class one and 
a complier class two. Individuals in the dCBT-I group 
were assigned values of 1 for class one and 0 for class two 
if they were non-compliers, and 0 for class one and 1 for 
class two if they were compliers. Individuals in the patient 
education group were assigned values of 1 for both class 
one and class two, to indicate that they were allowed to be 
a member of either class. As such, compliers and non-
compliers with valid outcome data at week 9 were included 
in the CACE analysis (n=1117).
We also did exploratory subgroup analyses in which 
the multiple group feature in Mplus (type=mixture, 
known class) was used to examine treatment effect 
heterogeneity across subgroups defined by self-reported 
comorbidity rates or recruitment pathway (eg, via the 
media or a pri mary care facility). These subgroups were 
not pre-defined in the protocol. A Wald test was used to 
determine the joint significance of the treatment-by-
subgroup inter action, and within-subgroup treatment 
effects are reported.
This trial is registered with ClinicalTrials.gov 
(NCT02558647) and is ongoing, with 2-year follow-up 
analyses planned.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Participants were recruited between Feb 26, 2016, 
and July 1, 2018. 5349 individuals started the online scre-
ening process, of which 1497 did not meet the eligibility 
criteria or declined to participate, and a further 2131 dis -
continued the automated screening process before ran-
domisation (figure). Therefore, the trial sample included 
1721 participants, with a mean age of 45 years (SD 14; 
range 18–90). 1167 (68%) participants were female and 
1074 (62%) were married or cohabi ting (with data 
missing for one participant). Of the 1701 participants 
with available data, 1123 (66%) self-reported sleep prob-
lems for 6 years or more. Baseline characteristics are 
shown in table 2.
584 (67%) of the 868 participants randomly allocated to 
the dCBT-I group and 534 (63%) of the 853 allocated to 
the patient education group completed the ISI (the 
primary outcome measure) at the 9-week follow-up. In 
the dCBT-I group, 748 (86%) participants completed the 
first core of the dCBT-I programme, and 402 (46%) 
completed all six during the intervention period (table 1). 
Attrition over time could not be measured in the patient 
education group because those individuals received 
access to all elements of the patient education inter-
vention following randomis ation. No adverse events 
were reported to the trial team.
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The latent growth model showed that participants in the 
dCBT-I group had a significantly greater reduction in ISI 
scores from baseline (mean score 19·2 [SD 3·9]) to 9-week 
follow-up (10·4 [6·2]) compared with those in the patient 
education group (from 19·6 [4·0] to 15·2 [5·3]; estimated 
mean difference –4·7 [95% CI –5·4 to –4·1]; 
Cohen’s d –1·21; p<0·001; table 3).
At the 9-week follow-up, 337 (58%) of 584 participants in 
the dCBT-I group met the ISI criteria for response 
compared with 113 (21%) of 534 in the patient education 
group, representing a difference of 37 percentage points 
(95% CI 31–42; p<0·001) in proportion of responders. 
219 (38%) participants in the dCBT-I group met the criteria 
for remission, compared with 41 (8%) in the patient 
education group (difference 30 percentage points [25–34]; 
p<0·001) in proportion of remitters. NNT analyses 
estimated that 2·7 (95% CI 2·4–3·2) individuals would 
need to receive dCBT-I for one additional individual to 
respond to the intervention compared with patient edu-
cation, and that 3·2 (2·8–3·8) individuals would need to 
receive dCBT-I for one additional individual to achieve 
remission.
Significant group-by-time interaction effects indicated 
that participants in the dCBT-I group had larger 
Figure: Trial profile
*An individual could be deemed ineligible on the basis of more than one inclusion or exclusion criterion. 
dCBT-I=digital cognitive behavioural therapy for insomnia.
5349 assessed for eligibility
1721 randomly allocated
3628 excluded or discontinued during automated screening*
2131 discontinued screening
844 Epworth Sleepiness Scale score >10
288 night-time shift work
266 Insomnia Severity Index score <12
161 declined to participate
126 sleep apnoea symptoms
93 bipolar disorder
28 recent heart surgery
24 epilepsy
868 allocated to dCBT-I group and 
completed baseline assessments
584 completed questionnaires at week 9
491 completed questionnaires and 
sleep diaries
93 completed questionnaires only 
868 included in intention-to-treat analyses
284 lost to follow-up or 
discontinued before week 9 
853 allocated to patient education group 
and completed baseline assessments
534 completed questionnaires at week 9
459 completed questionnaires and 
sleep diaries
75 completed questionnaires only
853 included in intention-to-treat analyses
319 lost to follow-up or 
discontinued before week 9
dCBT-I (n=868)* Patient education 
(n=853)
Age, years 44·2 (13·9) 44·8 (13·7)
Sex
Female 596 (69%) 571 (67%)
Male 271 (31%) 282 (33%)
Missing data 1 (<1%) 0
Years in education 16·4 (3·0) 16·2 (2·9)
Employment status
Full-time employment 427 (49%) 427 (50%)
Part-time employment 122 (14%) 120 (14%)
Unemployed 61 (7%) 46 (5%)
Retired 74 (9%) 74 (9%)
Student 69 (8%) 67 (8%)
Other 114 (13%) 119 (14%)
Missing data 1 (<1%) 0
Married or cohabiting with partner
Yes 539 (62%) 535 (63%)
No 328 (38%) 318 (37%)
Missing data 1 (<1%) 0
Children living in household
Yes 303 (35%) 317 (37%)
No 564 (65%) 535 (63%)
Missing data 1 (<1%) 1 (<1%)
Sleep problem duration
<6 months 29 (3%) 19 (2%)
6–11 months 16 (2%) 17 (2%)
1–5 years 246 (28%) 251 (29%)
6–10 years 226 (26%) 216 (25%)
>10 years 343 (40%) 338 (40%)
Missing data 8 (1%) 12 (1%)
Checks email daily
Yes 801 (92%) 781 (92%)
No 66 (8%) 72 (8%)
Missing data 1 (<1%) 0
Uses internet daily
Yes 851 (98%) 837 (98%)
No 16 (2%) 15 (2%)
Missing data 1 (<1%) 1 (<1%)
Very comfortable with internet
Yes 724 (83%) 708 (83%)
No 143 (16%) 145 (17%)
Missing data 1 (<1%) 0
Comorbidity
Medical condition 102 (12%) 109 (13%)
Mental health condition 303 (35%) 286 (34%)
Medical and mental health 
condition
81 (9%) 118 (14%)
No comorbidity 380 (44%) 339 (40%)
Missing data 2 (<1%) 1 (<1%)
Data are mean (SD) or n (%). dCBT-I=digital cognitive behavioural therapy for 
insomnia. *One participant had missing data for all variables.
Table 2: Baseline characteristics
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improve ments than those in the patient education group 
for most secondary measures (table 3). For example, par-
ticipants in the dCBT-I group were significantly less 
likely than those in the control group to be using sleep 
medi cations at follow-up, with the reduction in preva-
lence of sleep medication use from baseline to follow-up 
dCBT-I Patient education Intervention effect
n Value* n Value* Estimate† (95% CI) Cohen’s d (95% CI) p value
Insomnia measure
Insomnia Severity Index score
Baseline 867 19·2 (3·9) 853 19·6 (4·0) ·· ·· ··
Week 9 584 10·4 (6·2) 534 15·2 (5·3) –4·7 (–5·4 to –4·1) –1·21 (–1·38 to –1·05) <0·001
Bergen Insomnia Scale score
Baseline 867 27·9 (7·4) 853 28·0 (7·6) ·· ·· ··
Week 9 584 14·8 (9·8) 534 21·6 (9·4) –7·1 (–8·1 to –6·0) –0·94 (–1·08 to –0·80) <0·001
Sleep diary measures
Sleep onset latency (min)
Baseline 868 55·0 (42·8) 853 55·7 (47·3) ·· ·· ··
Week 9 490 31·1 (34·5) 459 46·4 (42·0) –15·6 (–20·0 to –11·1) –0·35 (–0·45 to –0·24) <0·001
Wake time after sleep onset (min)
Baseline 868 45·5 (40·4) 853 44·6 (37·5) ·· ·· ··
Week 9 490 24·7 (27·1) 459 35·1 (34·6) –12·3 (–16·2 to –8·4) –0·32 (–0·42 to –0·22) <0·001
Early morning awakening (min)
Baseline 868 41·6 (34·0) 853 43·3 (39·2) ·· ·· ··
Week 9 490 18·9 (18·9) 459 33·0 (30·9) –12·9 (–16·7 to –9·2) –0·35 (–0·48 to –0·23) <0·001
Time in bed (h)
Baseline 868 8·3 (1·0) 853 8·2 (1·0) ·· ·· ··
Week 9 490 7·5 (1·1) 459 8·1 (1·0) –0·6 (–0·7 to –0·5) –0·60 (–0·72 to –0·47) <0·001
Total sleep time (h)
Baseline 868 5·9 (1·2) 853 5·9 (1·2) ·· ·· ··
Week 9 490 6·3 (1·1) 459 6·2 (1·2) 0·1 (0·0 to 0·2) 0·07 (–0·03 to 0·17) 0·154
Sleep efficiency (%)
Baseline 868 71·9 (13·4) 853 71·5 (13·3) ·· ·· ··
Week 9 490 83·6 (10·5) 459 76·5 (13·2) 7·1 (5·7 to 8·5) 0·54 (0·43 to 0·64) <0·001
Daytime function and mental health measures
Psychological distress (HADS total score)
Baseline 867 13·2 (6·9) 853 13·4 (7·2) ·· ·· ··
Week 9 584 10·2 (7·0) 534 11·5 (7·0) –1·2 (–1·8 to –0·6) –0·17 (–0·26 to –0·09) <0·001
Chalder Fatigue Questionnaire score
Baseline 867 20·8 (5·9) 853 20·9 (6·0) ·· ·· ··
Week 9 584 15·4 (7·2) 534 17·6 (6·4) –2·4 (–3·1 to –1·6) –0·40 (–0·53 to –0·27) <0·001
SF-12 physical health score
Baseline 867 41·7 (6·8) 853 41·8 (6·9) ·· ·· ··
Week 9 584 41·5 (6·6) 584 41·6 (6·6) 0·3 (–0·4 to 1·0) 0·05 (–0·06 to 0·15) 0·378
SF-12 mental health score
Baseline 867 36·3 (11·4) 853 35·8 (11·3) ·· ·· ··
Week 9 584 42·9 (12·6) 584 39·2 (11·7) 3·2 (1·9 to 4·4) 0·28 (0·17 to 0·39) <0·001
Use of over-the-counter or prescription medication(s) for sleep (“yes” or “no”)
Sleep medication use (“yes”)
Baseline 868 480 (55·3%) 853 514 (60·3%) ·· ·· ··
Week 9 490 191 (39·0%) 459 230 (50·1%) 0·49 (0·23 to 0·74) ·· 0·007
dCBT-I=digital cognitive behavioural therapy for insomnia. HADS=Hospital Anxiety and Depression Scale. SF-12=12-Item Short-Form Health Survey. *Data are mean (SD) for 
continuous variables or n (%) for categorical variables. †For continuous variables, intervention effect is presented as the between-group difference in the mean change from 
baseline to week 9 (change in dCBT-I group minus change in patient education group); for categorical variables, intervention effect is presented as odds ratio in the dCBT-I 
group versus the patient education group. 
Table 3: Results from intention-to-treat latent growth model for primary and secondary outcomes
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estimated to be around 16 percentage points for dCBT-I 
and 10 percentage points for patient education (odds 
ratio 0·49 [95% CI 0·23 to 0·74]; p<0·001). Compared 
with the participants in the patient education group, the 
dCBT-I group showed a significantly greater reduction in 
fatigue on the basis of CFQ scores (Cohen’s d –0·40 [95% CI 
–0·53 to –0·27]; p<0·001). There were no differences 
between the groups in terms of total sleep time or 
perceived physical health (SF-12 physical health score).
The complier-average causal effect estimation for the 
ISI score resulted in a slightly larger effect size 
(Cohen’s d –1·78 [–1·97 to –1·59]; p<0·001) than that 
found in the intention-to-treat analysis.
Sensitivity analyses of primary and secondary outcomes 
with last observation carried forward produced decreased 
between-group effect sizes, although the differences 
found to be significant in the main analyses remained so 
in the sensitivity analyses (appendix pp 3–5). When 
missing post-intervention scores on the ISI were replaced 
by pre-intervention scores multiplied by 1·25 in the 
dCBT-I group and by 1·0 or 0·75 in the patient education 
group, the analysis yielded effect sizes (Cohen’s d) of 
–0·51 (–0·67 to –0·35; p<0·001) and –0·03 (–0·18 to 0·13; 
p=0·73), respectively.
The treatment-by-subgroup effect was not statistically 
significant for comorbidity (pinteraction=0·69) or recruitment 
source (pinteraction=0·74) suggesting that the intervention 
was equally effective across corresponding subgroups 
(appendix pp 7–8). Given the exploratory nature of these 
analyses, the results should be interpreted with caution.
Discussion
This study is one of the largest RCTs to date to examine 
the efficacy of fully automated dCBT-I in a community-
based sample of adults with high levels of insomnia. It is 
also the largest RCT to evaluate efficacy with the recom-
mended standard outcomes for insomnia (ie, changes in 
ISI ratings and sleep–wake patterns as assessed using 
sleep diaries).9 At the 9-week follow-up assessment, 38% 
of participants in the dCBT-I group met the ISI criteria for 
remission (<8 points), compared with only 8% of those in 
the patient education group. A similar pattern was 
observed for the proportion of participants with a 
response on the ISI, which is espe cially noteworthy given 
that a greater reduc tion in the prevalence of sleep 
medication use was seen in the dCBT-I group than in the 
patient education group from baseline to week 9. Overall, 
the dCBT-I group achieved signifi cantly better insomnia 
outcomes while reducing their reliance on sleep 
medication. Importantly, dCBT-I also reduced daytime 
fatigue and led to improve ments in other key markers of 
health and well being, including psychological distress 
and perceived mental health.
Overall, our findings support those obtained in previous 
high-quality trials on the effects of fully auto mated dCBT-I 
for individuals with insomnia.5–8 The between-group 
effect size on ISI score was –1·21 in favour of dCBT-I. 
On this basis, dCBT-I compares favourably to standalone 
self-help interventions that have fewer interactive and 
tailored elements than SHUTi, and the effect size is well 
within the range of that typically found with face-to-face 
therapies and the most successful therapist-guided 
dCBT-I interventions.25,26 To date, as no robust RCTs 
comparing fully automated interventions with guided or 
face-to-face therapies have been published, it is not 
possible to draw firm conclusions about the superiority of 
one such inter vention over the other. Our trial showed 
NNTs of around three for response or remission based on 
the ISI. This finding is consistent with findings from 
smaller-scale dCBT-I trials reported in a meta-analysis,26 
but is particu larly important because the NNT with 
hypnotics can be more than ten27 (and use of these 
medications is not recommended in the long term2).
This study is the first large-scale, fully automated 
dCBT-I trial to report significant changes in the use of 
sleep medication during the course of therapy. These 
findings contrast with those of another RCT (n=303) of 
fully automated dCBT-I compared with patient education, 
which showed no group-by-time interaction effect on 
medication use.5 This difference might be due to the 
greater sample size and statistical power in our trial, as 
well as differences in the operationalisation of medication 
use. However, another RCT (n=148) showed that therapist 
guided dCBT-I was associated with less use of sleep 
medication up to 3 years after the intervention, compared 
to an active control group.28
More research is needed on the possible negative 
effects of dCBT, the key moderators and mediators of any 
therapeutic effects, and early dropout or disengagement. 
In addition, it will be useful to explore how dCBT-I can be 
integrated into stepped or accelerated care models, espe-
cially in the primary health system. Although rapid 
imple mentation of new evidence-based innovations is 
important, it is also important to monitor the degree to 
which their efficacy (as shown in RCTs) transfers to 
clinical contexts.
Several limitations of this trial should be noted. First, 
of the more than 5000 potential participants who 
initiated the online screening test, more than 
2000 discontinued for unknown reasons before rea-
ching the randomisation process. In addition, 65% of 
participants completed the questionnaires and 55% 
completed the sleep diaries at the post-intervention 
assessment, making the represen tativeness of the 
sample unclear. However, these com pletion rates are 
well within an acceptable range, although lower than 
that typically achieved in well conducted face-to-face 
trials of CBT for insomnia, such as Edinger and collea-
gues’ study.29
Participants were also self-identified, which might res-
trict the generalisability of the results. The female 
preponderance (68%) suggests a skewed distribution; 
however, a higher prevalence of insomnia is typically 
reported in women, and women tend to seek treatment for 
See Online for appendix
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insomnia more often than men. In addition, the average 
time in education was somewhat higher (equi valent to a 
completed Bachelor’s degree) than that in the gen eral 
Norwegian population (in which 34% have a higher edu-
cation degree).
This report covers only the short-term effects of dCBT-I 
(according to the a priori analysis plan),12 resulting in 
uncertainty regarding the durability of the effects.
Furthermore, in this trial, other sleep difficulties were 
not assessed (with the exception of symptoms of sleep 
apnoea, which was an exclusion criterion). Thus, there is 
a risk that some cases might have been misidentified as 
insomnia (eg, restless legs). We reported participants’ 
medication use as measured with a single, non-specific 
question from the sleep diary, without distinguishing 
between medication type or dose. It is also unclear whe-
ther nights without sleep medication in the diary reflect a 
discontinuation of sleep medication.
Another limitation is that only self-report data were 
used in the current trial. However, all variables were 
based on standardised questionnaires, and many of the 
targeted outcomes (eg, insomnia and psy cho logical 
distress) are subjective by their very nature. Nevertheless, 
future trials should include objective mea sures of the 
effects of dCBT-I, including the effects on sleep and 
medication use. 
Regarding intervention use, slightly less than 50% of 
individuals allocated to dCBT-I completed all six core 
elements of the intervention, which compares fav-
ourably with rates of about 18–48% in other large-scale 
dCBT-I trials.7,8 A previous trial investigating use of the 
SHUTi programme in an adult sample found that 
60% of participants completed all six cores of the pro-
gramme.5 As a practical comparison, in the USA, about 
40% of patients with chronic conditions collect their 
prescribed medication and take it correctly.30
Our findings provide scientific support that a self-
guided dCBT-I programme made widely accessible could 
be effective in reducing both night-time and daytime 
impairments associated with the insomnia disorder, 
while also reducing the likelihood of sleep medication 
use in adults with high levels of insomnia. Although the 
findings support a widespread dissemination of dCBT-I, 
it is still unclear how to optimally disseminate and target 
such interventions.
Contributors
ØV, HK, and BS conceived the study. All authors contributed to study 
design. ØV produced the first draft of the manuscript with specific input 
from HK, JS, and BS. ORFS did all analyses masked to group allocation. 
All authors assisted in drafting of the final, submitted version of 
manuscript and all authors have approved this version.
Declaration of interests
FPT and LMR report financial or business interests in BeHealth Solutions 
and Pear Therapeutics, two companies that develop and disseminate 
digital therapeutics (including by licensing the therapeutic developed) 
based in part on early versions of the software from the University of 
Virginia, which is used in the research reported in this Article. These 
companies had no role in preparing this manuscript. LMR is also a 
consultant to Mahana Therapeutics, a separate digital therapeutic 
company not affiliated with this research. Some of the research in this 
Article was done while FPT was a faculty member at the University 
of Virginia. The terms of these arrangements have been reviewed and 
approved by the University of Virginia (for FPT and LMR) in accordance 
with its policies. All other authors declare no competing interests.
Data sharing
De-identified data that underlie the results reported in this Article will 
be available to researchers from accredited research institutions. Access 
to data will be limited to investigators who provide a methodologically 
sound proposal and will be limited to a specified time period 
(commencing about 3 months after publication of this Article and 
ending after 5 years). To ensure compliance with the General Data 
Protection Regulation, data processing must be covered by the 
European Commission’s standard contractual clauses for the transfer 
of personal data, which must be signed by the data requesters. Proposals 
and requests for data access should be directed to the corresponding 
author. User-friendly output from the trial will be disseminated to 
patient advocacy and other relevant organisations.
Acknowledgments
This trial is supported by the Norwegian Research Council (grant 
number 239985) and the Liaison Committee for Education, Research 
and Innovation in Central Norway (grant number 90061500). We thank 
the patient user group for the Central Norway Health Trust (Regionalt 
brukerutvalg, Helse Midt-Norge) for their contributions to the design 
of the trial.
References
1 National Institute for Health and Care Excellence. Insomnia. 
January, 2020. https://cks.nice.org.uk/insomnia (accessed 
June 30, 2020).
2 Pallesen S, Sivertsen B, Nordhus IH, Bjorvatn B. A 10-year trend 
of insomnia prevalence in the adult Norwegian population. 
Sleep Med 2014; 15: 173–79.
3 Riemann D, Baglioni C, Bassetti C, et al. European guideline for the 
diagnosis and treatment of insomnia. J Sleep Res 2017; 26: 675–700.
4 Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical 
guideline for the evaluation and management of chronic insomnia 
in adults. J Clin Sleep Med 2008; 4: 487–504.
5 Ritterband LM, Thorndike FP, Ingersoll KS, et al. Effect of 
a web-based cognitive behavior therapy for insomnia intervention 
with 1-year follow-up: a randomized clinical trial. JAMA Psychiatry 
2017; 74: 68–75.
6 Christensen H, Batterham PJ, Gosling JA, et al. Effectiveness 
of an online insomnia program (SHUTi) for prevention of 
depressive episodes (the GoodNight Study): a randomised 
controlled trial. Lancet Psychiatry 2016; 3: 333–41.
7 Espie CA, Emsley R, Kyle SD, et al. Effect of digital cognitive 
behavioral therapy for insomnia on health, psychological 
well-being, and sleep-related quality of life: a randomized clinical 
trial. JAMA Psychiatry 2019; 76: 21–30.
8 Freeman D, Sheaves B, Goodwin GM, et al. The effects of improving 
sleep on mental health (OASIS): a randomised controlled trial with 
mediation analysis. Lancet Psychiatry 2017; 4: 749–58.
9 Buysse DJ, Ancoli-Israel S, Edinger JD, Lichstein KL, Morin CM. 
Recommendations for a standard research assessment of insomnia. 
Sleep 2006; 29: 1155–73.
10 Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia 
Severity Index: psychometric indicators to detect insomnia cases 
and evaluate treatment response. Sleep (Basel) 2011; 34: 601–08.
11 Johns MW. A new method for measuring daytime sleepiness: 
the Epworth sleepiness scale. Sleep 1991; 14: 540–45.
12 Kallestad H, Vedaa Ø, Scott J, et al. Overcoming insomnia: protocol 
for a large-scale randomised controlled trial of online cognitive 
behaviour therapy for insomnia compared with online patient 
education about sleep. BMJ Open 2018; 8: e025152.
13 Hagatun S, Vedaa O, Nordgreen T, et al. The short-term efficacy 
of an unguided internet-based cognitive-behavioral therapy for 
insomnia: a randomized controlled trial with a six-month 
nonrandomized follow-up. Behav Sleep Med 2019; 17: 137–55.
14 Ritterband LM, Thorndike FP, Gonder-Frederick LA, et al. 
Efficacy of an internet-based behavioral intervention for adults 
with insomnia. Arch Gen Psychiatry 2009; 66: 692–98.
Articles
e406 www.thelancet.com/digital-health   Vol 2   August 2020
15 Morin CM. Insomnia: psychological assessment and management. 
New York: Guilford Press, 1993.
16 Thorndike FP, Saylor DK, Bailey ET, Gonder-Frederick L, 
Morin CM, Ritterband LM. Development and perceived utility 
and impact of an Internet intervention for insomnia. 
E J Appl Psychol 2008; 4: 32–42.
17 Carney CE, Buysse DJ, Ancoli-Israel S, et al. The consensus sleep 
diary: standardizing prospective sleep self-monitoring. Sleep (Basel) 
2012; 35: 287–302.
18 Pallesen S, Bjorvatn B, Nordhus IH, Sivertsen B, Hjørnevik M, 
Morin CM. A new scale for measuring insomnia: the Bergen 
Insomnia Scale. Percept Mot Skills 2008; 107: 691–706.
19 American Psychiatric Association. Diagnostic and statistical 
manual of mental disorders, 4th edn, text revision (DSM-IV-TR). 
Washington, DC: American Psychiatric Association, 2000.
20 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983; 67: 361–70.
21 Chalder T, Berelowitz G, Pawlikowska T, et al. Development 
of a fatigue scale. J Psychosom Res 1993; 37: 147–53.
22 Ware J Jr, Kosinski M, Keller SDA. A 12-Item Short-Form Health 
Survey: construction of scales and preliminary tests of reliability 
and validity. Med Care 1996; 34: 220–33.
23 Enders CK. Applied missing data analysis. New York, NY: 
Guilford Press, 2010.
24 Citrome L. Compelling or irrelevant? Using number needed 
to treat can help decide. Acta Psychiatr Scand 2008; 117: 412–19.
25 van Straten A, van der Zweerde T, Kleiboer A, Cuijpers P, 
Morin CM, Lancee J. Cognitive and behavioral therapies in 
the treatment of insomnia: a meta-analysis. Sleep Med Rev 
2018; 38: 3–16.
26 Zachariae R, Lyby MS, Ritterband LM, O’Toole MS. Efficacy 
of internet-delivered cognitive-behavioral therapy for 
insomnia—a systematic review and meta-analysis of randomised 
controlled trials. Sleep Med Rev 2016; 30: 1–10.
27 Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative 
hypnotics in older people with insomnia: meta-analysis of risks 
and benefits. BMJ 2005; 331: 1169.
28 Blom K, Jernelöv S, Rück C, Lindefors N, Kaldo V. Three-year 
follow-up of insomnia and hypnotics after controlled internet 
treatment for insomnia. Sleep (Basel) 2016; 39: 1267–74.
29 Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. 
Cognitive behavioral therapy for treatment of chronic primary 
insomnia: a randomized controlled trial. JAMA 2001; 285: 1856–64.
30 Neiman AB, Ruppar T, Ho M, et al. CDC grand rounds: improving 
medication adherence for chronic disease management—innovations 
and opportunities. MMWR Morb Mortal Wkly Rep 2017; 66: 1248–51.
